SBIO Fact Sheet: ALPS Medical Breakthroughs ETF
Share
$52.90
close, Nov 18, 2026
Over the year to Nov 18, 2026, SBIO returned +13.0% in total and charged 0.50% a year.
- 1-year total return
- +13.0%
- to Nov 18, 2026
- Expense ratio
- 0.50%
- a year
- Net flow, 12 months to Aug 31, 2026
- +$81.7m
- monthly N-PORT basis to Aug 31, 2026
Growth of $10,000, 1 year
SBIO $11,304 +13.0% · Total return, distributions reinvested, Nov 18, 2025 to Nov 18, 2026.
Returns
WindowTotal return
1 month+1.5%
3 months−25.3%
Year to date+3.3%
1 year+13.0%
3 years+114.9%
5 years+22.1%
Total return, distributions reinvested, each window to Nov 18, 2026.
Ten largest positions
HoldingWeight
Crinetics Pharmaceuticals Inc4.60%
Apogee Therapeutics Inc4.29%
Cg Oncology Inc3.41%
Travere Therapeutics Inc3.17%
Xenon Pharmaceuticals Inc2.99%
Dianthus Therapeutics Inc2.96%
Oruka Therapeutics Inc2.87%
Acadia Pharmaceuticals Inc2.54%
Edgewise Therapeutics Inc2.31%
Definium Therapeutics Inc2.23%
SBIO top ten by weight, 31.4% of the fund, of its 103 equity positions, from the holdings filed for Aug 31, 2026.
Facts
Equity fund · Tracks the S-Network Medical Breakthroughs Index · First traded Dec 31, 2014 · Benchmark Its own holdings, as of Aug 31, 2026